Drug Trial Radar · NCT04740671
A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD
Last checked: Nov 20, 2026Latest source record: Jan 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
410
Actual
Start
Jul 1, 2021
Primary completion
Dec 31, 2024
Study completion Dec 31, 2024
Sponsor
- Lead sponsor
- Shanghai Henlius BiotechIndustry
- Sponsor type
- Industry
- First posted
- Feb 5, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will compare the efficacy and safety of HLX04-O administered by intravitreal injection (IVT) with ranibizumab in patients with active wAMD.
Conditions
- Age Related Macular Degeneration
Interventions
HLX04-ODrug
Biologic recombinant anti-VEGF humanized monoclonal antibody, developed by Shanghai Henlius Biotech, Inc.
ranibizumabDrug
Biologic anti-VEGF recombinant humanized monoclonal antibody fragment
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean change from baseline in BCVA at at Week 36Time frame: up to at Week 36
Locations
126 sites in 15 countries. Site status is shown where the registry gives one.
Associated Retina Consultants-Gilbert
Gilbert, Arizona
Associated Retina Consultants-Phoenix
Phoenix, Arizona
Retina Consultants of Orange County
Fullerton, California
Global Research Management
Glendale, California
Atlantis Eyecare, VMR Institute
Huntington Beach, California
VMR Institute
Huntington Beach, California
South Coast Retina Center
Long Beach, California
Retina Consultants of Orange County
Los Alamitos, California
MACRO Trials/ Lazar Retina
Los Angeles, California
East West Eye Institute
Torrance, California
Retina Consultants of Southern Colorado
Colorado Springs, Colorado
Florida Retina Institute-Orlando
Jacksonville, Florida
Florida Retina Institute-Orlando
Orlando, Florida
University of South Florida
Tampa, Florida
Center for Retina and Macular Disease
Winter Haven, Florida
Southeast Retina Center
Augusta, Georgia
The University of Chicago, IL
Chicago, Illinois
The University of Chicago
Chicago, Illinois
Illinois Retina Associates
Oak Park, Illinois
Retina Associates LLC
Lenexa, Kansas
Butchertown Clinical Trials
Louisville, Kentucky
Cumberland Valley Retina Consultants
Hagerstown, Maryland
Retina Consultants of Minnesota
Edina, Minnesota
VitreoRetinal Surgery PLLC DBA Retina Consultants of Minnesota
Saint Louis Park, Minnesota
Mississippi Retina Associates
Jackson, Mississippi
Piedmont Retina Specialists
Asheville, North Carolina
Western Carolina Retinal Associates
Asheville, North Carolina
Graystone Eye
Hickory, North Carolina
North Carolina Retina Associates
Wake Forest, North Carolina
Verum Research, LLC
Eugene, Oregon
Retina Consultants of Charleston - Beaufort
Beaufort, South Carolina
Retina Consultants of Charleston: Charleston Neuroscience Institute
Charleston, South Carolina
Carolina Center for Sight
Florence, South Carolina
Retina Consultants of Nashville
Nashville, Tennessee
Retina Consultants of TEXAS- Newcastle
Bellaire, Texas
Mt. Olympus Research-Garcia
Houston, Texas
Mt. Olympus Research/Museum Eye District
Houston, Texas
Retina Consultants of TEXAS - Round Rock
Round Rock, Texas
Retina Consultants of Texas
The Woodlands, Texas
Retina Associates of Utah, PLLC
Salt Lake City, Utah
Showing 40 of 126 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.